Clinical trial, phase 1, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Spike protein, SARS-CoV-2, Molecular clamp
influenza virus, vaccine, antibodies, A(H3N2), antigenic change, genetic change, evolution